HepQuant to Hold 2017 Scientific Advisory Board October 21st in Washington, DC
DENVER (August 31, 2017) — HepQuant, LLC, a diagnostics company, located in Greenwood Village, CO with unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced
today announced it will be holding its 2017b Scientific Advisory Board Meeting in Washington D.C. on Saturday, October 21st. HepQuant continues to work with thought leaders in the field of hepatology to optimize current and future research, development, and commercialization of its technology for measuring global liver function.
HepQuant will be hosting this meeting while attending The Liver Meeting® 2017, or the 69th AASLD Annual Meeting. This is not an official function/event of the American Association for the Study of Liver Diseases.
HepQuant products are investigational combination drug / diagnostic devices and have not yet been evaluated or approved by the US Food and Drug Administration (FDA) for commercial sale. They are currently available for investigational use via the FDA IDE application process. For additional information, please visit our website at www.hepquant.com.
Brad Everson, Chief Business Development Officer
Ph: (720) 600-3651 | E: firstname.lastname@example.org
Tom Kennedy, Corporate Communications
Ph: (303) 548-3056